Chengdu Sainuo Biopharmaceutical

Chengdu Sainuo Biopharmaceutical is a specialized pharmaceutical company based in Chengdu, China, focusing on the development and manufacture of peptide-based therapeutics. Established in 1993, the company has built a robust infrastructure for the large-scale synthesis of peptides using both solid-phase and liquid-phase methodologies. Its commercial portfolio features essential treatments such as Thymopentin for immune modulation, Somatostatin for acute gastrointestinal bleeding, and Oxytocin for obstetric care. Sainuo operates state-of-the-art GMP-certified facilities that produce both active pharmaceutical ingredients (APIs) and finished dosage forms, including lyophilized powders and small-volume injections. The company serves a broad market, providing high-quality peptide products to healthcare providers across China and internationally. Through its commitment to quality and innovation in peptide chemistry, Sainuo has established itself as a key player in the Chinese biopharmaceutical landscape.